AutoGenomics Names Salvatore Alberti Chief Financial Officer

Vista, Calif -- AutoGenomics, Inc., announced today that it has named Salvatore V. Alberti as Chief Financial Officer.
 
 
Spread the Word
Listed Under

Tags:
AutoGenomics
Microarray-based
Diagnostic Platfrom
INFINITI HTS

Industrys:
Health
Medical

Location:
Vista - California - US

Subject:
Executives

VISTA, Calif. - May 29, 2014 - PRLog -- Mr. Alberti has over 20 years of financial leadership experience in both privately held and publicly owned companies.  He has held roles as Chief Financial Officer, Corporate Controller, Senior Director of SEC Reporting, and International Controller and has held senior financial management positions with BeyondTrust Software, Solera Holdings,  ActivIdentity and Linear Technology Corporation.  Mr. Alberti has six years combined experience in public accounting with Ernst & Young and Deloitte. He holds a B.S. in Business Administration (Accounting) and a M.S. in Accountancy from San Diego State University. Mr. Alberti is a Certified Public Accountant in the State of California.

“We are very happy to welcome Sal to AutoGenomics” said Fareed Kureshy, AutoGenomics’ President and Chief Executive Officer.  “As we grow our business with the introduction of the INFINITI® High Throughput System (HTS) and expand our menu of tests, Sal’s broad business background will be important as we seek to expand our investor base to capitalize on our leadership position in the molecular diagnostics market.”

About AutoGenomics

AutoGenomics Inc., a privately held company based in Vista, CA, designs, develops, manufactures and markets an automated, microarray-based multiplexing diagnostic platform that can be used to assess disease signatures with novel genomic and proteomic markers in the areas of personalized medicine, women’s health, oncology, genetic disorders and infectious disease.  With the discovery of genes and their link to various disease states, the AutoGenomics platform revolutionizes the way patients are diagnosed, monitored and managed, leading to a new and emerging era of personalized medicine and significant advances in drug selection and dosing.    www.autogenomics.com

Contact
Fareed Kureshy
***@autogenomics.com
End
Source:
Email:***@autogenomics.com
Posted By:***@autogenomics.com Email Verified
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
AutoGenomics Inc. PRs
Trending News
Top Daily News
Top Weekly News



Like PRLog?
9K2K1K
Click to Share